Medscape is available in 5 Language Editions – Choose your Edition here.


Neuronal Ceroid Lipofuscinoses Workup

  • Author: Celia H Chang, MD; Chief Editor: Amy Kao, MD  more...
Updated: Dec 14, 2015

Approach Considerations

Biochemical abnormalities in neuronal ceroid lipofuscinoses (NCLs) include the accumulation of subunit C of the ATP synthase complex (SCMAS) in the lysosomes of patients with mutations in CLN2, CLN3, CLN4, CLN5, CLN6, CLN7, or CLN8. In CLN3 NCL, a large proportion of lymphocytes contain cytoplasmic vacuoles.

Enzyme levels


Palmitoyl protein thioesterase (PPT) levels can be measured in leukocytes, cultured fibroblasts, dried blood spots, and saliva. Lymphoblast PPT is less than 0.2pmoles/min/mg (normal levels are 1-3).[19]


Tripeptidyl peptidase 1 (TTP1) levels can be measured in leukocytes, cultured fibroblasts, dried blood spots, and saliva. Fibroblast TTP1 activity is approximately 17,000 micromoles of amino acids produced per hour per mg of protein. The TTP1 activity in CLN2 NCL is less than 4% of normal.[19, 20]


Electroencephalographic characteristics seen in CLN1 NCL (infantile form) include the following:

  • Lack of attenuation of posterior dominant rhythm to eye opening
  • Loss of sleep spindles
  • Progressive background abnormality and attenuation with the background flat by age 3 years

In CLN2 NCL, occipital spikes with photic stimulation at 1-2 Hz are seen on electroencephalograms (EEGs). In CLN3 NCL, the results are disorganized, and spike and slow wave complexes are seen.


On electroretinography, characteristics include the following:

  • CLN1 NCL (infantile form) - Unrecordable at age 3 years
  • CLN1 NCL (juvenile form) - Unrecordable at diagnosis
  • CLN2 NCL (late-infantile form) - Abnormal at presentation and then extinguishes
  • CLN3 NCL - Abnormal early

Visual evoked potential

Visual evoked-potential studies are characterized as follows:

  • CLN1 NCL (infantile form) - Unrecordable at age 4 years
  • CLN2 NCL (late-infantile form) - Abnormally enhanced, but diminish in the final stages
  • CLN3 NCL - Abnormal early

Somatosensory evoked potential

Progressive attenuation in all NCLs is seen in somatosensory evoked-potential studies.


In CLN2 NCL, Worgall et al found that the Weill Cornell late-infantile NCL (LINCL) scale correlated better than the modified Hamburg LINCL scale did with age and time since the onset of initial clinical manifestations. In addition, they found that imaging measures also correlated better with the Weill Cornell scale.[21]


MRI and MR Spectroscopy


Magnetic resonance imaging (MRI) findings in CLN1 NCL include the following:

  • Mild cerebral atrophy progresses after 4
  • Decreased T2-signal intensity in the thalami
  • Callosal thinning
  • Periventricular rims of hyperintensity that progress to diffuse white matter hyperintensity on T2
  • Cerebellar atrophy after age 3 years

In magnetic resonance (MR) spectroscopy, the following characteristics are seen in CLN1 NCL:

  • Almost complete loss of N- acetylaspartate (metabolite present only in neurons)
  • Reduction in creatine- and choline-containing compounds (ie, markers for glial membrane turnover)
  • Elevation of myoinositol (ie, a glial marker)
  • Elevation of lactate in gray and white matter


In CLN2 NCL, progressive atrophy, especially infratentorial atrophy, is seen. In a study, Dyke et al found that a whole-brain apparent diffusion coefficient (ADC) correlated with the patient's age and disease duration. They determined that children in the study with CLN2 began to differ from controls at age 5 years.[22]


MRI findings in CLN3 NCL include the following:

  • Cerebral atrophy
  • Cerebellar atrophy usually after age 15 years
  • In voxel-based morphometric study [23] - Marked reduction in the gray matter volume of the dorsomedial thalami in particular and decreased white matter volume of the corona radiata are seen


MRI findings in CLN6 NCL include severe cerebral and cerebellar atrophy.


PET Scanning

In positron emission tomography (PET) scanning, the following characteristics are seen:

  • CLN2 NCL - Severe, generalized hypometabolism
  • CLN3 NCL - Hypometabolism, earliest in the calcarine area

DNA Testing

DNA testing and electron microscopic ultrastructural findings in peripheral blood lymphocytes[24] may be used, as well as other tissues. Resources such as can be used to determine updated availability of genetic testing on a clinical or research basis. DNA testing considerations regarding CLN genes include the following:

  • Infantile NCL (INCL) - CLN1 gene localizes to chromosome 1p32 [Granular osmiophilic deposits = GROD]
  • Late-infantile NCL (LINCL) - CLN2 gene localizes to chromosome 11p15.5 [Curvilinear bodies = CV/Mixed]
  • Juvenile NCL (JNCL) - CLN3 gene localizes to chromosome 16p12.1 [Fingerprint profiles = FP/mixed]
  • Adult NCL (ANCL) - CLN4 gene not mapped yet [FP/granular]
  • Finnish variant late-infantile NCL (fLINCL) - CLN5 gene localizes to chromosome 13q21.1-q32 [FP, CV, rectilinear complex = RL]
  • Portuguese variant late-infantile NCL (pLINCL) - CLN6 gene localizes to chromosome 15q21-q23 [CV, FP, RL]
  • Turkish variant late-infantile NCL (tLINCL) - CLN7 gene mapped to 4q28.1-q28.2 [FP/mixed]
  • Progressive epilepsy with mental retardation (PEMR) - CLN8 gene localizes to chromosome 8p23 [CV or GROD-like inclusions]
  • CLN9 [GROD, CV, FP]


Histologic findings in CLN1 NCL include an almost complete loss of cortical neurons. In CLN3 NCL, findings include vacuolated lymphocytes, as well as selective necrosis of stellate cells in layers II and III and loss of pyramidal cells in layer V.

Findings in CLN5 NCL include the following:

  • Neuronal loss in the neocortex and cerebellum
  • Laminar pattern of neuronal loss, most severe in layers III and V
  • Meganeurites in layer III
  • Extensive gliosis
  • Almost complete loss of Purkinje and granule cells with gliosis

Findings in CLN6 NCL include the following:

  • Neuronal loss, especially layer V
  • Loss of granule cells, with relative preservation of Purkinje cells
  • SCMAS absent in liver, adrenals, and pancreas

Findings in CLN8 NCL include the following:

  • Slight loss in layer V and CA2 in hippocampus
  • SCMAS most prominent in layer III and hippocampus CA2-CA4
  • Meganeurites in layer III
  • Minimal SCMAS in Purkinje cells, substantia nigra, and locus ceruleus
  • Unlike other lysosomal storage diseases, usually no ectopic dendritic growth or axonal spheroids
  • Meganeurites caused by distention of the axon hillock and proximal axon (occasionally)
Contributor Information and Disclosures

Celia H Chang, MD Health Sciences Clinical Professor, Chief, Division of Child Neurology, Department of Neurology/MIND Institute, University of California, Davis, School of Medicine

Celia H Chang, MD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Have stock from Cellectar Biosciences; have stock from Varian medical systems; have stock from Express Scripts.


Beth A Pletcher, MD Associate Professor, Co-Director of The Neurofibromatosis Center of New Jersey, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Beth A Pletcher, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

  1. Mole S. UCL. NCL Resource - A gateway for Batten disease. Available at

  2. Dolisca SB, Mehta M, Pearce DA, Mink JW, Maria BL. Batten Disease: Clinical Aspects, Molecular Mechanisms, Translational Science, and Future Directions. J Child Neurol. 2013 Jul 9. [Medline].

  3. Bennett MJ, Rakheja D. The neuronal ceroid-lipofuscinoses. Dev Disabil Res Rev. 2013 Jun. 17(3):254-9. [Medline].

  4. Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013 Sep. 28 (9):1101-5. [Medline].

  5. Cialone J, Adams H, Augustine EF, et al. Females experience a more severe disease course in batten disease. J Inherit Metab Dis. 2011 Dec 14. [Medline].

  6. Persaud-Sawin DA, Mousallem T, Wang C, Zucker A, Kominami E, Boustany RM. Neuronal ceroid lipofuscinosis: a common pathway?. Pediatr Res. 2007 Feb. 61(2):146-52. [Medline].

  7. Miller JN, Pearce DA. A Novel c.776_777insA Mutation in CLN1 Leads to Infantile Neuronal Ceroid Lipofuscinosis. J Child Neurol. 2013 Jul 14. [Medline].

  8. Lyly A, von Schantz C, Salonen T, Kopra O, Saarela J, Jauhiainen M, et al. Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)--distinct characteristics in neurons. BMC Cell Biol. 2007 Jun 12. 8:22. [Medline].

  9. Hobert JA, Dawson G. A novel role of the Batten disease gene CLN3: association with BMP synthesis. Biochem Biophys Res Commun. 2007 Jun 22. 358(1):111-6. [Medline].

  10. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, et al. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet. 2007 Jul. 81(1):136-46. [Medline].

  11. Schulz A, Dhar S, Rylova S. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol. 2004 Sep. 56(3):342-50. [Medline].

  12. Schulz A, Mousallem T, Venkataramani M. The CLN9 protein, a regulator of dihydroceramide synthase. J Biol Chem. 2006 Feb 3. 281(5):2784-94. [Medline].

  13. Miao N, Levin SW, Baker EH, et al. Children with infantile neuronal ceroid lipofuscinosis have an increased risk of hypothermia and bradycardia during anesthesia. Anesth Analg. 2009 Aug. 109(2):372-8. [Medline]. [Full Text].

  14. Ostergaard JR, Rasmussen TB, Mølgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011 Apr 5. 76(14):1245-51. [Medline].

  15. Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies. J Child Neurol. 2007 May. 22(5):621-7. [Medline].

  16. Backman ML, Santavuori PR, Aberg LE. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005 Jan. 49(Pt 1):25-32. [Medline].

  17. Online Mendelian Inheritance in Man. #610951 CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7. Online Mendelian Inheritance in Man. Available at Accessed: February 17, 2012.

  18. Schulz A, Dhar S, Rylova S, et al. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol. 2004 Sep. 56(3):342-50. [Medline].

  19. Kohan R, de Halac IN, Tapia Anzolini V. Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses. Clin Biochem. 2005 May. 38(5):492-4. [Medline].

  20. Chang X, Huang Y, Meng H, Jiang Y, Wu Y, Xiong H, et al. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses. Brain Dev. 2012 Jan 13. [Medline].

  21. Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007 Aug 7. 69(6):521-35. [Medline].

  22. Dyke JP, Voss HU, Sondhi D, Hackett NR, Worgall S, Heier LA, et al. Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging. AJNR Am J Neuroradiol. 2007 Aug. 28(7):1232-6. [Medline].

  23. Autti T, Hämäläinen J, Aberg L, Lauronen L, Tyynelä J, Van Leemput K. Thalami and corona radiata in juvenile NCL (CLN3): a voxel-based morphometric study. Eur J Neurol. 2007 Apr. 14(4):447-50. [Medline].

  24. Anderson GW, Smith VV, Brooke I, Malone M, Sebire NJ. Diagnosis of neuronal ceroid lipofuscinosis (Batten disease) by electron microscopy in peripheral blood specimens. Ultrastruct Pathol. 2006 Sep-Oct. 30(5):373-8. [Medline].

  25. Hawkins-Salsbury JA, Cooper JD, Sands MS. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease). Biochim Biophys Acta. 2013 Nov. 1832(11):1906-9. [Medline].

  26. Kohan R, Cismondi IA, Oller-Ramirez AM, et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol. 2011 Jun. 12(6):867-83. [Medline].

  27. Kinarivala N, Trippier PC. Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). J Med Chem. 2015 Nov 24. [Medline].

  28. Selden NR, Al-Uzri A, Steiner R, Huhn SL. 126 CNS Stem Cell Transplantation for Neuronal Ceroid Lipofuscinoses: Summary of Long-term Follow-up Study Results. Neurosurgery. 2013 Aug. 60 Suppl 1:161-2. [Medline].

  29. Crystal RG, Sondhi D, Hackett NR. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther. 2004 Nov. 15(11):1131-54. [Medline].

  30. Griffey M, Macauley SL, Ogilvie JM. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther. 2005 Sep. 12(3):413-21. [Medline].

  31. Hackett NR, Redmond DE, Sondhi D. Safety of Direct Administration of AAV2(CU)hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates. Hum Gene Ther. 2005 Nov 30. [Medline].

  32. Sondhi D, Peterson DA, Giannaris EL. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 2005 Nov. 12(22):1618-32. [Medline].

  33. Fowler DJ, Anderson G, Vellodi A, Malone M, Sebire NJ. Electron microscopy of chorionic villus samples for prenatal diagnosis of lysosomal storage disorders. Ultrastruct Pathol. 2007 Jan-Feb. 31(1):15-21. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.